스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

erol ab - folsyra, vattenfri - orala droppar, lösning - 10 mg/ml - glycerol hjälpämne; folsyra, vattenfri 10 mg aktiv substans; propylenglykol hjälpämne - folsyra

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 200 mg - dexibuprofen 200 mg aktiv substans

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 400 mg - dexibuprofen 400 mg aktiv substans

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 300 mg - dexibuprofen 300 mg aktiv substans

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

nordic drugs ab - dexibuprofen - filmdragerad tablett - 300 mg - dexibuprofen 300 mg aktiv substans - dexibuprofen

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

nordic drugs ab - dexibuprofen - filmdragerad tablett - 400 mg - dexibuprofen 400 mg aktiv substans - dexibuprofen

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - carcinom, non-small cell lung - antineoplastiska medel - giotrif som monoterapi är indicerat för behandling ofepidermal growth factor receptor (egfr) tki-naiva vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer (nsclc) med aktiverande egfr-mutation(s), lokalt avancerad eller metastaserad icke-småcellig lungcancer av skivepitelcancer histologi framåt på eller efter platinum-baserad kemoterapi.

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinom, non-small cell lung - antineoplastiska medel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, non-small cell lung - antineoplastiska medel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiska medel - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.